V
Voyager Acquisition Corp./Cayman Islands
VACHUCIK 0002006815NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)E9FY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$8.99M
Total Assets
$270.06M
Equity
$-13.15M
Shares Out
25.30M
Op. Cash Flow
$-486.2K
Business
Voyager Acquisition Corp./Cayman Islands is a blank check company that seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar initial business combination. It offers units comprising Class A ordinary shares and warrants and pursues structuring and financing alternatives to complete a business combination. The company operates through management and a board that focus on sourcing, diligence and transaction execution with an emphasis on healthcare and healthcare‑related industries. It sources targets through proprietary networks, private channels and public market listing processes and may pursue opportunities in any geography.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| General and administrative expenses | 2 | 702,959 | |
| Loss from operations | −2 | −702,959 | |
| Interest income | 11,435 | 9,552 | |
| Income from investments held in Trust Account | 11 | 5 | |
| Unrealized gain on investments held in Trust Account | — | 159,076 | |
| Total other income | 11 | 5 | |
| Net income | 9 | 4 | |
| Weighted average shares outstanding of Class A redeemable ordinary shares, basic and diluted | 25 | 10 | |
| Basic and diluted net income per ordinary share, Class A Redeemable ordinary shares | 0.28 | 0.26 | |
| Weighted average shares outstanding of Class B ordinary shares, basic | 6 | 6 | |
| Basic net income per ordinary share, Class B ordinary shares | 0.28 | 0.26 | |
| Weighted average shares outstanding of Class B ordinary shares, diluted | 6 | 6 | |
| Diluted net income per ordinary share, Class B ordinary shares | 0.28 | 0.24 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 182,103 | 668,285 | — | |
| Due from Sponsor | — | 44,028 | — | |
| Prepaid assets | 11,537 | — | — | |
| Total current assets | 193,640 | 712,313 | — | |
| Investments and Cash in Trust Account | 270 | 259 | — | |
| Total Assets | 270 | 260 | 71,680 | |
| Accounts payable and accrued expenses | 1 | 5,054 | 5,000 | |
| Due to related party | 238,200 | 33,913 | — | |
| Due to Sponsor | 646 | — | — | |
| Total current liabilities | 1 | 38,967 | 76,680 | |
| Deferred underwriting commissions | 12 | 12 | — | |
| Total Liabilities | 13 | 12 | 76,680 | |
| Class A ordinary shares, $0.0001 par value; 25,300,000 shares subject to possible redemption at $10.67 and $10.24 per share as of December 31, 2025 and 2024, respectively | 270 | 259 | — | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding at December 31, 2025 and 2024 | — | — | — | |
| Additional paid-in capital | — | — | — | |
| Accumulated deficit | −13 | −11 | −5,000 | |
| Total shareholders deficit | −13 | −11 | −5,000 | |
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders Deficit | 270 | 260 | 71,680 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Income from investments held in Trust account | −11 | −5 | |
| Increase in prepaid assets | −11,537 | — | |
| Increase in accounts payable and accrued expenses | 1 | 54 | |
| Decrease (increase) in amount due from Sponsor | 44,674 | −74,028 | |
| Increase in amount payable to related party | 204,287 | 63,913 | |
| Net cash used in operating activities | −486,182 | −703,468 | |
| Cash deposited in Trust Account | — | −254 | |
| Net cash used in investing activities | — | −254 | |
| Issuance of shares to Sponsor | — | 25,000 | |
| Gross proceeds from initial public offering | — | 253 | |
| Proceeds from private placement | — | 8 | |
| Payment of offering costs | — | −5 | |
| Reimbursement of underwriter expenses | — | −52,860 | |
| Net cash provided by financing activities | — | 256 | |
| Net (decrease) increase in cash | −486,182 | 668,285 | |
| Deferred underwriting fee payable | — | 12 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro